Structure Therapeutics (NASDAQ:GPCR) Earns Overweight Rating from Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of Structure Therapeutics (NASDAQ:GPCR) in a report issued on Monday morning, Benzinga reports. They currently have a $65.00 price objective on the stock.

Several other analysts have also recently weighed in on GPCR. JMP Securities reaffirmed a market outperform rating and issued a $91.00 target price on shares of Structure Therapeutics in a report on Friday, May 10th. JPMorgan Chase & Co. began coverage on shares of Structure Therapeutics in a research note on Tuesday, May 21st. They set an overweight rating and a $65.00 target price for the company. Finally, BMO Capital Markets raised their price target on Structure Therapeutics from $83.00 to $100.00 and gave the company an outperform rating in a research note on Friday, June 7th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Structure Therapeutics currently has an average rating of Buy and a consensus target price of $85.25.

Structure Therapeutics Trading Down 3.3 %

Shares of NASDAQ GPCR opened at $37.45 on Monday. The stock has a market cap of $1.75 billion, a P/E ratio of -48.64 and a beta of -3.59. The business’s fifty day simple moving average is $41.74 and its 200-day simple moving average is $41.21. Structure Therapeutics has a 12-month low of $25.57 and a 12-month high of $75.02.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.02. On average, equities analysts forecast that Structure Therapeutics will post -0.94 EPS for the current fiscal year.

Hedge Funds Weigh In On Structure Therapeutics

Hedge funds have recently made changes to their positions in the company. Teachers Retirement System of The State of Kentucky boosted its position in shares of Structure Therapeutics by 17.8% in the 1st quarter. Teachers Retirement System of The State of Kentucky now owns 13,733 shares of the company’s stock valued at $589,000 after purchasing an additional 2,077 shares during the period. Virtu Financial LLC purchased a new stake in Structure Therapeutics in the first quarter valued at approximately $308,000. RA Capital Management L.P. boosted its holdings in shares of Structure Therapeutics by 210.2% in the first quarter. RA Capital Management L.P. now owns 1,510,362 shares of the company’s stock valued at $64,734,000 after acquiring an additional 1,023,530 shares during the period. Artal Group S.A. grew its position in shares of Structure Therapeutics by 75.3% during the first quarter. Artal Group S.A. now owns 151,780 shares of the company’s stock worth $6,505,000 after acquiring an additional 65,180 shares during the last quarter. Finally, Janus Henderson Group PLC increased its holdings in shares of Structure Therapeutics by 34.5% in the 1st quarter. Janus Henderson Group PLC now owns 2,076,700 shares of the company’s stock valued at $88,994,000 after acquiring an additional 532,284 shares during the period. Hedge funds and other institutional investors own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.